Where vaptans do and do not fit in the treatment of hyponatremia

Kidney International

Volumn 83, Issue 4, 2013, Pages 563-567

  Jovanovich, Anna J ^a   Berl, Tomas ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

hyponatremia; vasopressin; vasopressin antagonist

Indexed keywords

AMINO ACID TRANSPORTER; CONIVAPTAN; DEMECLOCYCLINE; DESMOPRESSIN; ISOTONIC SOLUTION; LOOP DIURETIC AGENT; PLACEBO; SODIUM CHLORIDE; SODIUM DEPENDENT NEUTRAL AMINO ACID TRANSPORTER 2; TOLVAPTAN; UNCLASSIFIED DRUG; UREA DERIVATIVE; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ANTIDIURESIS; BRAIN EDEMA; CRUSH SYNDROME; DRUG EFFICACY; HUMAN; HYPONATREMIA; MORBIDITY; MORTALITY; NEPHROGENIC SYNDROME; NOCTURIA; NONHUMAN; POLYURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; SYMPTOMATOLOGY; THIRST; WATER DEPRIVATION; XEROSTOMIA;

EID: 84875730113     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.402     Document Type: Short Survey

References (40)

1. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009; 122: 857-865.
2. Kovesdy CP, Lott EH, Lu JL. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012; 125: 677-684.
3. Waikar SS, Curhan GC, Brunelli SM. Mortality associated with low serum concentration in maintenance hemodialysis. Am J Med 2011; 124: 77-84.
4. Rozen-Zvi B, Yahav D, Gheorghiade M et al. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis 2010; 56: 325-337.
5. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69: 2124-2130.
6. Koenig MA, Bryan M, Lewin JL III. Reversal of transtentorial herniation with hypertonic saline. Neurology 2008; 70: 1023-1029.
7. Sterns RH, Cappucio JD, Silver SM et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4: 1522-1530.
8. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
9. Velez JC, Dopson SJ, Sanders DS et al. Intravenous conivaptan for the treatment of hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Neprhol Dial Transplant 2010; 25: 1524-1531.
10. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and morality. JAMA 1999; 281: 2299-2304.
11. Berl T. Treating hyponatremia: damned if we do and damned if we don't. Kidney Int 1990; 37: 1006-1018.
12. Gangkam-Kengne F, Nicaise C, Soupart A et al. Astrocytes are an early target in osmotic demyelination syndrome. J Am Soc Nephrol 2011; 22: 1834-1845.
13. Gankam-Kengne F, Soupart A, Pochet R et al. Minocycline protects against neurologic complication of rapid correction of hyponatremia. J Am Soc Nephrol 2010; 21: 2099-2108.
14. Franchi-Gazzola R, Dall'Asta V, Sala R et al. The role of the neutral amino acid transporter SNAT2 in cell volume regulation. Acta Physiol 2006; 187: 273-283.
15. Soupart A, Ngassa M, Decauz G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol 1999; 51: 383-386.
16. Oya S, Tsutsumi K, Ueki K et al. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology 2001; 57: 1931-1932.
17. Schwartz WB, Bennet W, Curelop S et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957; 23: 529-542.
18. Thurman JM, Berl T. Therapy of dysnatremic disorders. In: Wilcox C ed Therapy in Nephrology and Hypertension. Saunders Elsevier: Philadelphia, 2008, pp 337-352.
19. Perianayagam A, Sterns RH, Silver SM. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008; 3: 331-336.
20. Sterns RH, Hix JK, Silver S. Treating profound hyponatremia: a strategy for controlled correction. Am J Kidney Dis 2010; 56: 774-779.
21. Decaux G, Andres C, Gankam Kengne F et al. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care 2010; 14: R184.
22. Jaber BL, Almarzouqi L, Borgi L et al. Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. Am J Med 2011; 124: 977.e1-9.
23. Schrier RW. Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol 2010; 6: 185.
24. Renneboog B, Musch W, Vandemergel X et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119: 71.e1-8.
25. Gankam Kengne F, Andres C, Sattar L et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008; 101: 583-588.
26. Sandhu HS, Gilles E, DeVita MV et al. Hyponatremia associated with large-bone fracture in elderly patients. Int Urol Nephrol 2009; 41: 733-737.
27. Hoorn EJ, Rivadeneira F, van Meurs JB et al. Mild hyponatremia as a risk factor for fractures: the Rotterdam Study. J Bone Miner Res 2011; 26: 1822-1828.
28. Verbalis JG, Barsony J, Sugimura Y et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010; 25: 554-563.
29. Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem 2011; 286: 10864-10875.
30. Furst H, Hallows KR, Post J et al. The urine/plasma electrolyute ratio: a predictive guide to water restriction. Am J Med Sci 2000; 319: 240-244.
31. Decaux G, Waterlot Y, Genette F et al. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide. N Engl J Med 1981; 304: 329-330.
32. Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 2008; 19: 1076-1078.
33. Soupart A, Coffernils M, Courturier B et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patient with SIADH. Clin J Am Soc Nephrol 2012; 7: 742-747.
34. Berl T, Quittnat-Pelletier F, Verbalis JG et al. Oral Tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21: 705-712.
35. Soupart A, Gross P, Legros JJ et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006; 1: 1154-1160.
36. Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med 1982; 72: 339-353.
37. Feldman BJ, Rosenthal SM, Vargas GA et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005; 352: 1884-1890.
38. Decaux G, Vandergheynst F, Bouko Y et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007; 18: 606-612.
39. Ranchin B, Boury-Jamot M, Blanchard G et al. Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion. J Clin Endocrinol Metab 2010; 95: E37-E43.
40. Cserr HF, Depasqualle M, Patlak CS. Regulation of brain water and electrolytes during acute hyponatremia in rats. Am J Physiol 1987; 254: F522-F529.